Physician profile
Meir Daller
NPI 1386656528
$3,087.35
in general payments reported to CMS, 2019-2025
23 companies · $25.40 in 2025
The $25.40 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $745 · 2021: $920 · 2022: $459 · 2023: $21.99 · 2025: $25.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $494.17 | 2019-2022 | |
| Astellas Pharma US INC | $478.83 | 2019-2021 | |
| Antares Pharma, INC. | $432.96 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Coloplast Corp | $210.15 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $199.58 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $170.36 | 2019 | |
| Pfizer INC. | $149.05 | 2019-2021 | |
| Clarus Therapeutics INC. | $128.08 | 2021 | |
| Blue Earth Diagnostics | $121.76 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.04 | 2020-2022 | |
| Dendreon Pharmaceuticals LLC | $103.87 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $89.79 | 2021-2022 | |
| Janssen Biotech, INC. | $70.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $69.60 | 2021-2022 | |
| Urovant Sciences INC | $68.53 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $52.49 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $36.32 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $25.40 | 2025 | Azmiro |
| Boston Scientific Corporation | $20.32 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.76 | 2019 | |
| Convatec INC. | $16.02 | 2020 | |
| Metuchen Pharmaceuticals | $11.77 | 2020 | |
| Amgen INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meir Daller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.